Amy Sullivan - 23 Dec 2024 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: Chief Financial Officer
Issuer ticker: IOBT
Reported as of: 23 Dec 2024
Net transaction value: +$8,483
SEC form: 4
Accepted by SEC: 23 Dec 2024, 18:53:56 UTC
Prior SEC filing: 18 Mar 2024
Next SEC filing: 04 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Amy Sullivan

Key filing fact

Amy Sullivan filed Form 4 for IO Biotech, Inc. (IOBT) on 23 Dec 2024.

Key facts

This page summarizes Amy Sullivan's Form 4 filing for IO Biotech, Inc. (IOBT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Dec 2024, 18:53.

Change

Previous filing in this sequence was filed on 18 Mar 2024.
Current net transaction value: +$8,483.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IOBT transaction

Common Stock

Purchase

Transaction value: $8,483
Shares: +10,250
Change %: +14%
Price: $0.8276
Shares after: 84,632
Date: 23 Dec 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The transaction was executed in multiple trades in prices ranging from $0.7861 to $0.90, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.